Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueDepreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsReceivables - NetReceivables - Other
Ratios

Akebia Therapeutics (AKBA) Other Gross PP&E Adjustments (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Other Gross PP&E Adjustments for 9 consecutive years, with -$5.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 45.6% to -$5.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.3 million, a 45.6% increase, with the full-year FY2025 number at -$5.3 million, up 45.6% from a year prior.
  • Other Gross PP&E Adjustments was -$5.3 million for Q4 2025 at Akebia Therapeutics, up from -$6.4 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$5.3 million in Q4 2025 to a low of -$32.6 million in Q1 2022.
  • A 5-year average of -$18.4 million and a median of -$16.5 million in 2023 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: plummeted 43.16% in 2021, then surged 55.78% in 2023.
  • Akebia Therapeutics' Other Gross PP&E Adjustments stood at -$28.6 million in 2021, then rose by 19.86% to -$22.9 million in 2022, then grew by 18.93% to -$18.6 million in 2023, then soared by 48.01% to -$9.7 million in 2024, then soared by 45.6% to -$5.3 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Other Gross PP&E Adjustments are -$5.3 million (Q4 2025), -$6.4 million (Q3 2025), and -$7.6 million (Q2 2025).